

Novartis India Limited

July 29, 2026

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500 672

Subject: Disclosure in terms of Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.

Dear Sir/ Madam,

Pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, please find enclosed herewith the disclosure in Form C received from Novartis AG, Erstwhile

Promoter of the Company, in respect of the Sale of 1,74,50,680 (One Crore Seventy-Four Lakhs Fifty Thousand Six Hundred and Eighty Only) equity shares of the Company representing 70.68% (Seventy point Sixty-Eight) of the share capital.

The disclosure was received by the Company on Wednesday, July 29, 2026.

The disclosure will also be made available on the Company's website at www.nilpharma.co.in.

Kindly take the above information on record and acknowledge receipt.

**Yours sincerely,
For Novartis India Limited**

**Chandni Maru
Company Secretary and Compliance Officer
A60291**

Encl as above:



Novartis AG
CH-4002 Basel
Switzerland

<https://www.novartis.com>
<https://x.com/novartisnews>

July 29, 2026

To,
The Board of Directors
Novartis India Limited
Inspire BKC, 7th Floor,
Bandra Kurla Complex,
Bandra East, Mumbai 400051,
Maharashtra, India.

Dear Sir,

Subject: Disclosure in terms of Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015

We, Novartis AG, hereby make this disclosure pursuant to Regulation 7(2) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.


We request you to kindly take the above on record and acknowledge receipt.

Sincerely,

[Signature pages follow]

Yours faithfully,

For and on behalf of **NOVARTIS AG**

A handwritten signature in blue ink, consisting of a stylized 'E' followed by a long horizontal line.

Name: *Eric Green*

Designation: *Attorney*

Yours faithfully,

For and on behalf of **NOVARTIS AG**



Name: OLIVER WATSON

Designation: AUTHORIZED SIGNATORY

Form C

Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015

[Regulation 7(2) read with Regulation 6(2) – Continual Disclosure]

Name of Target Company : Novartis India Limited

ISIN of the Company : INE234A01025

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2):														
Name, PAN No. CIN/DIN & address of with contact nos.	Category of Person (Promoter/m ember of the promoter group/design ated person / Director s/immediate relative to/others etc.)	Securities held prior to acquisition-/ disposal		Securities - acquired /Disposed				Securities held post acquisition / disposal		Date(s) of Allotment advice/ acquisition of shares / disposal of shares, specify		Date of inti mation to Com pan y	Mode of acquisit ion / disposa l	Exchange on which the trade was executed
		Type of securit y	No. and % of shareho lding	Type of securi ty	No.	Value (In Rs.)	Transaction Type (Buy/ Sale/Pledge / Revoke/ Invoice)	Type of secu rity	No. and % of sharehol ding	Fro m	To			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Name: Novartis AG PAN No.: AAACN4932F	Promoter	Equity Shares	1,74,50, 680 shares represen ting	Equity Share s	1,74,5 0,680	INR 13,76,8 8,87,28 1	Sale	NIL	NIL	July 29, 2026		July 29, 2026	Off- market sale	NA

Enterprise Identification Number (UID): CHE-103.867.266			70.68% of the share capital										
Address: Lichtstrasse 35, 4056 Basel, Switzerland Contact No.: +41 61 324 11 11													
Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2):													
Trading in derivatives (Specify type of contract, Futures or Options etc.)												Exchange on which the trade was executed	
Type of Contract	Contract Specifications	Buy				Sell							
		Notional Value	Number of units (Contracts lot size)		Notional Value	Number of units (Contracts lot size)							
16	17	18		19		20	21	22					
NIL												NIL	


Note:

- (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.
- (ii) Value of transaction excludes taxes/brokerage/any other charges.
- (iii) In case of Options, notional value shall be calculated based on Premium plus strike price of options.

[Signature pages follow]

Yours faithfully,

For and on behalf of **NOVARTIS AG**

A handwritten signature in blue ink, appearing to read 'Eric Carreau', written over a horizontal line.

Name: *Eric Carreau*

Designation: *Attorney*

Yours faithfully,

For and on behalf of **NOVARTIS AG**



Name: **OLIVER WATSON**

Designation: **AUTHORISED SIGNATORY**